To highlight dasatinib role in the elderly, 125 unselected patients with CP-CML aged >60 years resistant/intolerant to imatinib were retrospectively evaluated. Grade 3-4 haematological and extra-haematological toxicities were reported in 39 (31.2%) and 34 (27.2%) patients; grade 3-4 haematological toxicity was higher in patients with 140. mg starting dose (50.0% vs 19.6%, p = 0.001). Grade 3-4 pleuro-pericardial effusions occurred in 10 patients (8.0%). Dose reductions were more common in patients with 140. mg (88.4% vs 26.7%, p< 0.001). Of 122 evaluable patients, 72 (59.1%) had cytogenetic response [12 (9.8%) partial, 60 (49.3%) complete]. Overall, 38/60 patients in complete CyR also achieved a molecular response. Cumulative OS at 24 and 48 months were 93.1% (95% CI 88.4-97.8) and 84.2% (95% CI 74.6-93.7). Dasatinib, at the recommended dose of 100. mg/day, is effective and safe also in unselected elderly subjects.
Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib / R.Latagliata ; M. Breccia ; F.Castagnetti ; F.Stagno ; L.Luciano ; A.Gozzini ; S.Ulisciani ; F.Cavazzini ; M.Annunziata ; F.Sorà ; AR.Rossi ; P.Pregno ; E.Montefusco ; E.Abruzzese ; E.Crisà ; P.Musto ; M.Tiribelli ; G.Binotto ; U.Occhini ;C. Feo ;P.Vigneri ; V.Santini ; C.Fava ; G.Rosti ; G. Alimena. - In: LEUKEMIA RESEARCH. - ISSN 0145-2126. - STAMPA. - 35:(2011), pp. 1164-1169. [10.1016/j.leukres.2011.05.015]
Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib.
SANTINI, VALERIA;
2011
Abstract
To highlight dasatinib role in the elderly, 125 unselected patients with CP-CML aged >60 years resistant/intolerant to imatinib were retrospectively evaluated. Grade 3-4 haematological and extra-haematological toxicities were reported in 39 (31.2%) and 34 (27.2%) patients; grade 3-4 haematological toxicity was higher in patients with 140. mg starting dose (50.0% vs 19.6%, p = 0.001). Grade 3-4 pleuro-pericardial effusions occurred in 10 patients (8.0%). Dose reductions were more common in patients with 140. mg (88.4% vs 26.7%, p< 0.001). Of 122 evaluable patients, 72 (59.1%) had cytogenetic response [12 (9.8%) partial, 60 (49.3%) complete]. Overall, 38/60 patients in complete CyR also achieved a molecular response. Cumulative OS at 24 and 48 months were 93.1% (95% CI 88.4-97.8) and 84.2% (95% CI 74.6-93.7). Dasatinib, at the recommended dose of 100. mg/day, is effective and safe also in unselected elderly subjects.File | Dimensione | Formato | |
---|---|---|---|
1-s2.0-S0145212611002323-main.pdf
accesso aperto
Descrizione: Articolo
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Open Access
Dimensione
382.38 kB
Formato
Adobe PDF
|
382.38 kB | Adobe PDF |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.